Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Birju D. Bhatt¹, J. Lynn Palmer², Jeffrey R. Curtis³, Sathya Velkuru⁴ and Joel Kremer⁵, ¹Medicine, div-of Rheumatology, Albany Medical College, Albany, NY, ²Corrona Research Foundation, Albany, NY, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, Albany Medical College, Albany, NY, ⁵Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…
Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting
Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Ash Maroof¹, Remi Okoye¹, Tim Smallie¹, Dominique Baeten^2,3, Sophie Archer¹, Catherine Simpson¹, Meryn Griffiths¹ and Stevan Shaw¹, ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, Brussels, Belgium, ³University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…
Abstract Number: 1577 • 2017 ACR/ARHP Annual Meeting
Deciphering the Role of the Tissue Microenvironment in Shaping the Immune Landscape in Psoriatic Arthritis
Jin Hui Sherlynn Chan¹, Ying Ying Leung², Warren Fong², Yi Wei Yeo², Bhairav Paleja¹, Liyun Lai¹, Suzan Saidin¹, Camillus Chua¹, Sharifah Nur Hazirah¹, Su Li Poh¹, Andrea Hsiu Ling Low² and Salvatore Albani^1,3, ¹SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: Psoriatic arthritis (PsA) occurs in a third of patients with psoriasis (Ps) and up to 30% of patients with PsA do not have an…
Abstract Number: 36 • 2017 Pediatric Rheumatology Symposium
The Association of Obesity with Pediatric Psoriatic Arthritis
Cynthia Manos¹, Rui Xiao², Timothy G. Brandon¹, Alexis Ogdie-Beatty³ and Pamela Weiss⁴, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Obesity is associated with a significantly increased risk of inflammatory arthritis in adult patients with psoriasis. Obese adults with psoriatic arthritis (PsA) also…
Abstract Number: 937 • 2016 ACR/ARHP Annual Meeting
Distal Interphalangeal Joint Erosions Assessed By HR-pQCT in Patients with Psoriatic Onycholysis
Axel Patrice VILLANI¹, Stéphanie Boutroy², Hubert Marotte Sr.³, Loïs Barets⁴, Marie-Christine Carlier⁵, Roland Chapurlat⁶, Denis Jullien¹ and Cyrille B Confavreux⁷, ¹Dermatology, Hôpital Edouard Herriot, Dermatology department, Lyon I University, Lyon, France, ²Lyon I University, Inserm UMR1033, Lyon, France, ³CHU de St Etienne, Service de rhumatologie, St Etienne, France, ⁴Rheumatology, Hôpital Edouard Herriot, Lyon, France, ⁵Biochemistry, Hôpital Edouard Herriot, Lyon, France, ⁶Rheumatology, Hôpital Edouard Herriot, Hospices Civils de Lyon, University of Lyon, Lyon, France, ⁷Hôpital Edouard Herriot, Hospices Civils de Lyon, University of Lyon, Lyon, France
Background/Purpose: A third of cases of skin psoriasis are complicated by potentially incapacitating psoriatic arthritis (PsA). Nail psoriasis, especially onycholysis, is present in more than…
Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Mark Berman¹, Daphna Paran¹, Yonatan Wolman¹ and Ori Elkayam², ¹Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…
Abstract Number: 962 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Atul A. Deodhar¹, Stefan Schreiber², Kunal Gandhi³, Todd Fox⁴, Corine Gaillez⁴ and Chetan Karyekar³, ¹Oregon Health & Science University, Portland, OR, ²Christian-Albrechts-Universität Kiel, Kiel, Germany, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis, active psoriatic arthritis (PsA)…
Abstract Number: 2765 • 2016 ACR/ARHP Annual Meeting
Practicing What We Preach? Do Psoriatic Arthritis Patients Treated at an Academic Medical Center Meet Caspar Criteria?
Sergio Schwartzman, Rima Abhyankar, Margaret Bogardus and Lisa Mandl, Hospital for Special Surgery, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is an autoimmune musculoskeletal disease with protean manifestations, and therefore can be difficult to diagnose. Although no diagnostic criteria are available, the…
Abstract Number: 1293 • 2016 ACR/ARHP Annual Meeting
Utility of Extremity Magnetic Resonance Imaging (eMRI) without Contrast Enhancement in Detecting Preclinical Psoriatic Arthritis
Ashish J Mathew¹, Jyoti Panwar², Paul Bird³, Renu George⁴ and Debashish Danda¹, ¹Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ²Christian Medical College, Vellore, India, Vellore, India, ³University of New South Wales, Sydney, Australia, Sydney, NSW, Australia, ⁴Dermatology, Christian Medical College, Vellore, India, Vellore, India
Background/Purpose: Between 8-39% of patients with cutaneous psoriasis may develop psoriatic arthritis (PsA). Subclinical inflammatory joint disease in patients with psoriasis is common. i,ii This study…
Abstract Number: 2769 • 2016 ACR/ARHP Annual Meeting
Does Gender Make a Difference in “Composite Psoriatic Disease Activity Index (CPDAI)” in Patients with Psoriatic Arthritis?
Gokce Kenar¹, Handan Yarkan², Berrin Zengin¹, Gerçek Can², Merih Birlik¹, Nurullah Akkoc¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey
Background/Purpose: “Composite psoriatic disease activity index (CPDAI)” includes 5 domains: peripheral joints, skin, enthesitis, dactylitis, and spinal manifestations in psoriatic arthritis (PsA) which is a…
Abstract Number: 1665 • 2016 ACR/ARHP Annual Meeting
Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease
Remy Pollock¹, Laila Zaman¹, Vinod Chandran² and Dafna D Gladman³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Heritable epigenetic phenomena may play a role in the parent-of-origin effect observed in psoriasis and psoriatic arthritis (PsA). A previous epigenome-wide association study (EWAS)…
Abstract Number: 3035 • 2016 ACR/ARHP Annual Meeting
Characterization of DC-STAMP+ T Cells, a CD3+CD4+ T Cell Subset Uniquely Present in Patients with Psoriatic Disease
Yahui Grace Chiu¹, Edward Schwarz², Richard Bell³, Dongge Li⁴, Nelson Huertas⁴, Cristy Bell⁵, Sharon Moorehead⁵, Debbie Campbell⁵, Changyong Feng⁶ and Christopher T. Ritchlin⁷, ¹Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Orthopedeatrics, University of Rochester, Rochester, NY, ³Pathology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁶Statistics, University of Rochester, Rochester, NY, ⁷Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease that affects over 650,000 Americans. Bone damage occurs in half of these patients within the first…
Abstract Number: 1684 • 2016 ACR/ARHP Annual Meeting
Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Christopher T. Ritchlin¹, Alan Menter², Philip J Mease³, Sunil Kalia⁴, Francisco Kerdel⁵, Shelly Kafka⁶, James Morgan⁶, Wayne Langholff⁷, Steve Fakharzadeh⁶, Kavitha Goyal⁶ and Alice Gottlieb⁸, ¹Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Baylor Research Institute, Dallas, TX, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵University of Miami, Miami, FL, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Tufts University School of Medicine (affiliation at the time of the study), Boston, MA
Background/Purpose: To describe the rates of serious infections (SI) in psoriasis (PsO) pts with psoriatic arthritis (PsA) from PSOLAR, & assess risk with biologic therapy.…
Abstract Number: 3185 • 2016 ACR/ARHP Annual Meeting
Sensitivity Analysis for the Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients
Uyen-Sa D.T. Nguyen^1,2, Yuqing Zhang², David T. Felson^2,3,4, Michael P. Lavalley⁵ and Hyon K. Choi⁶, ¹Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ⁵Biostatistics, Boston University School of Public Health, Boston, MA, ⁶Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Smoking is a strong risk factor for psoriasis and psoriatic arthritis, but several studies have found that smoking is inversely associated with the risk…
Abstract Number: 1685 • 2016 ACR/ARHP Annual Meeting
Updated Results for All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Philip J Mease¹, Alice Gottlieb², Alan Menter³, Christopher T. Ritchlin⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, Soumya Chakravarty⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷, Kavitha Goyal⁷ and Jose U. Scher^9,10, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Tufts University School of Medicine (affiliation at the time of the study), Boston, MA, ³Baylor Research Institute, Dallas, TX, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹New York University School of Medicine, New York, NY, ¹⁰Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: To describe characteristics & potential risk factors(including treatment exposure) for all-cause mortality & malignancies (excluding NMSC) in psoriasis (PsO) patients (pts) with psoriatic arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].